"Women treated for DCIS are routinely told that hormone therapy is off the table, full stop. That advice almost always comes from trials in invasive breast cancer, not DCIS — and the two are not the same disease. This conversation deserves the same honesty I tried to bring to the last video."
If you've had DCIS and you're now dealing with hot flushes, broken sleep or brain fog, you've probably already had one of two conversations with a doctor: a flat no, or a lot of hedging without anyone walking you through why. Here is the evidence underneath that answer — where the blanket "no" came from, why two trials asking the same question got different results, and why DCIS changes the calculation in ways that matter.
Where the "No" Comes From
The default answer to "can I use HRT after breast cancer" goes back to 2002, when the Women's Health Initiative reported a higher rate of breast cancer in women taking combined oestrogen and progestin. HRT prescribing dropped off a cliff almost overnight.
What's changed since then: not the underlying biology, but how much more precisely we understand it. Which progestogen is used, what route it takes into the body, and the individual woman's own cancer characteristics all turn out to matter far more than that single 2002 trial could capture. There is still no large randomised trial of HRT specifically in women with DCIS — everything below comes from trials in invasive breast cancer, and that distinction matters more than it might seem.
Two Trials, Same Question, Different Answers
Two trials, run at the same time in Scandinavia, tried to answer this question directly — and reached opposite conclusions.
This wasn't chance. HABITS enrolled more node-positive, higher-risk women, with more tamoxifen use alongside HRT. Stockholm was built specifically to avoid the progestogen exposure HABITS hadn't controlled for. Put side by side, what these two trials actually show is that how the hormone is given matters as much as whether it's given at all.
"HRT after breast cancer is dangerous" isn't the conclusion these two trials support. "The formulation determines the risk" is closer to it.
Tibolone — a synthetic steroid sometimes pitched as a gentler option — was tested against placebo in over 3,000 breast cancer survivors in the LIBERATE trial. This one wasn't ambiguous: tibolone significantly increased recurrence, and it's now specifically flagged as something to avoid in anyone with a breast cancer history. If you've been offered tibolone as the "safer" choice, it isn't — it's a different drug, with a clear result against it.
Why DCIS Isn't the Same Conversation
None of those three trials enrolled women with DCIS. They enrolled women with invasive breast cancer, many node-positive. DCIS is different — it's confined to the milk ducts, hasn't broken through to invade surrounding tissue, and in the vast majority of cases there's no lymph node involvement at all.
If the DCIS was oestrogen-receptor positive but has already been removed with clear margins, there's no residual disease left for oestrogen to stimulate. The risk under discussion is the risk of a new cancer arising independently, not of reactivating something that's already gone. That's a genuinely different conversation to the one HABITS and Stockholm were having.
If a sentinel node biopsy came back positive, that signals a small area of invasion the original sampling missed — and the conversation shifts back toward the more cautious end, with HABITS and Stockholm becoming directly relevant again.
Formulation Is (Almost) Everything
Oral oestrogen is processed by the liver first, which raises clotting factors and carries a small increase in clotting risk. Transdermal oestrogen — patches, gels, sprays — skips that step and is the better-evidenced choice for most women, breast cancer history or not.
The progestogen side is where the real differences show up. Older synthetic progestogens — medroxyprogesterone acetate, norethisterone — bind to several hormone receptors beyond the progesterone receptor itself, and that broader binding is linked to breast cell proliferation. Micronised progesterone binds far more selectively.
🇳🇿🇦🇺 Micronised progesterone is available in New Zealand and Australia as Utrogestan. If you're being offered a synthetic progestogen instead, it's entirely reasonable to ask whether Utrogestan is an option for you.
Where This Leaves You
If your DCIS was fully excised with clear margins, your nodes were never involved, and your menopausal symptoms are genuinely affecting your life, a permissive approach to HRT is clinically defensible. If there was a positive sentinel node, or any uncertainty about microinvasion, the decision needs to be more individualised, and the HABITS and Stockholm data become more directly relevant again.
This isn't a blanket yes any more than the old advice was a sound blanket no. It's a decision that depends on your excision margins, your nodal status, your symptom severity, and the formulation being offered — and it should be made with your own clinician, not extrapolated from a headline.
Questions Worth Asking
- Was my DCIS fully excised with clear margins, and is there any suggestion of microinvasion?
- Do we know my hormone receptor status, and does it change the approach?
- Which formulation and which progestogen would we use — and is micronised progesterone an option?
- What's the alternative, and what's the evidence behind it?
- How will we monitor things, and what would make us reconsider?
If you ask those questions and get a flat no with nothing underneath it, it's entirely reasonable to ask for a second opinion.
What to Take From This
DCIS is not invasive breast cancer, and the hormone therapy conversation that follows shouldn't be borrowed wholesale from trials that enrolled neither. Formulation changes the risk. Margins and nodal status change the risk. Symptom severity changes whether the trade-off is worth making at all.
What I want you to take from this is not a green light — but precision: precision about your own pathology, your own formulation options, and the right questions to ask before anyone gives you a flat answer either way.
Continue Reading: The DCIS Series
Book a consultation: mybreastcarecentre.co.nz · menopauseandme.co.nz